US 11806360
Compositions and methods for treating transthyretin (TTR) mediated amyloidosis
granted A61KA61K31/07A61K31/135
Quick answer
US patent 11806360 (Compositions and methods for treating transthyretin (TTR) mediated amyloidosis) held by Alnylam Pharmaceuticals, Inc. expires Mon Nov 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Alnylam Pharmaceuticals, Inc.
- Grant date
- Tue Nov 07 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Nov 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 27
- CPC classes
- A61K, A61K31/07, A61K31/135, A61K31/167, A61K31/341